NeuroMed Establishes East China Headquarters in Nanjing, Advances Brain-Computer Interface Commercialization

At present, brain science and brain-inspired intelligence are becoming the strategic high ground of global scientific and technological competition.Invasive brain-computer interfaces are the "core bridge" linking cutting-edge research and clinical translation.Since its establishment in 2017, NeuroEchos has consistently focused on this direction, gathering top research forces from Tsinghua University, Zhejiang University, and other institutions, and has gone throughEight Years of Hard Work,Successfully Approved the World's First 3.0T MRI-Compatible SEEG Intracranial Depth in 2024Department Electrode Class III Medical Device Registration Certificate。

3.0T MRI-Compatible SEEG Intracranial Depth Electrodes

The company has built a global industry-university-research collaborative network spanning institutions such as UCLA in the United States, the National University of Singapore, and the Chinese Academy of Sciences, and has successively received awards.National High-tech Enterprise, Specialized and Innovative Enterprise"Title."

NeuroEchos' decision to establish its East China headquarters and R&D center here not only actively responds to Nanjing's scientific, educational, and clinical advantages but also acknowledges the historical depth and systematic innovation capabilities of Gulou District. This collaboration represents a crucial step for the company in expanding across East China and influencing the entire country, as well as a deep integration of "Nanjing’s original innovation" and "Shenzhen’s industrialization efficiency."

Gulou is becoming an "accelerator" for technology transfer in the brain-computer interface field, a "connector" for industry-university-research collaboration, and a "gravitational field" for industrial clustering.

From Shenzhen Bay to Zijin Mountain, How Did This Innovation Relay Across Thousands of Miles Advance Efficiently in a Short Period?

Since the first outreach to Shenzhen by the Gulin High-Tech Zone in collaboration with the city's biopharmaceutical task force on November 18, 2025, Gulou District has actively followed up, with the dedicated working group ensuring efficient coordination. Within the following two months, multiple rounds of practical communication were completed, including return visits by the NeuroEchos team, joint discussions with experts from Nanjing University, and financing engagement with state-owned enterprise groups.

"Every communication with Gulou directly addresses the key needs of our industrial implementation — from carrier space to talent support, from policy alignment to capacity co-building, they have presented a clear and feasible path," said the founder of NeuroEchos. "It is precisely this professional, efficient, and lasting service sincerity that made us choose Gulou without hesitation."

On December 18, 2025, the two parties completed key对接regarding company establishment and financing matters; On January 12, 2026, Jiangsu (Nanjing) Brain-Computer Interface Research InstituteGMP PlantPlanning Seminar Held to Lay Foundation for Subsequent Product Scale Production. By January 20, 2026, Two Project Companies Officially Registered and Established — A Comprehensive Collaboration Spanning Policy, Capital, Technology, and Platform Finally Propelled This Leading Brain-Computer Interface Enterprise to Take Root in Nanjing Gulou.